Immunogenicity and safety of the 9-valent HPV vaccine in men

Vaccine

Volumn 33, Issue 48, 2015, Pages 6892-6901

  Castellsague X ^a   Giuliano, A R ^b   Goldstone, S ^c   Guevara, A ^d   Mogensen, O ^e   Palefsky, J M ^f   Group, T ^g   Shields, C ^g   Liu, K ^g   Maansson, R ^g   Luxembourg, A ^g   Kaplan, S S ^g  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d HOSPITAL PABLO TOBÓN URIBE   (Colombia)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cancer; HPV; Men; Papillomavirus; Vaccine

Indexed keywords

HUMAN PAPILLOMAVIRUS VACCINE (TYPES 6 11 16 18 31 33 45 52 58); UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; BREAST DISEASE; CHEMILUMINESCENCE IMMUNOASSAY; COMPLICATION; CONGENITAL DISORDER; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILIAL DISEASE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GENETIC DISORDER; GENITAL SYSTEM DISEASE; HEADACHE; HEART DISEASE; HEPATOBILIARY DISEASE; HETEROSEXUAL MALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; INFECTION; INFESTATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INJURY; INTOXICATION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALAISE; MALE; MEN WHO HAVE SEX WITH MEN; MENTAL DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; PALLIATIVE THERAPY; PREGNANCY DISORDER; PRIORITY JOURNAL; SEROCONVERSION; SKIN DISEASE; SUBCUTANEOUS TISSUE DISORDER; UROGENITAL TRACT DISEASE; VACCINATION; VASCULAR DISEASE; IMMUNIZATION; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84949746186     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.06.088     Document Type: Article

References (46)

1. Doorbar J., Quint W., Banks L., et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012, 30(Suppl. 5):F55-F70.
2. Forman D., de Martel C., Lacey C.J., et al. Global burden of human papillomavirus and related diseases. Vaccine 2012, 30(Suppl. 5):F12-F23.
3. Garland S.M., Hernandez-Avila M., Wheeler C.M., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(19):1928-1943.
4. FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356(19):1915-1927.
5. Joura E.A., Leodolter S., Hernandez-Avila M., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three clinical trials. Lancet 2007, 369:1693-1702.
6. Paavonen J., Jenkins D., Bosch F.X., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369(9580):2161-2170.
7. Brotherton J.M., Fridman M., May C.L., Chappell G., Saville A.M., Gertig D.M. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377(9783):2085-2092.
8. Powell S.E., Hariri S., Steinau M., et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 2012, 31(1):109-113.
9. Baldur-Felskov B., Dehlendorff C., Munk C., Kjaer S.K. Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women. J Natl Cancer Inst 2014, 106:460-467.
10. Crowe E., Pandeya N., Brotherton J.M., et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014, 348:g1458.
11. Tabrizi S.N., Brotherton J.M., Kaldor J.M., et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012, 206(11):1645-1651.
12. Kahn J.A., Brown D.R., Ding L., et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics 2012, 130(2):e249-e256.
13. Markowitz L.E., Hariri S., Lin C., et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013, 208(3):385-393.
14. Read T.R., Hocking J.S., Chen M.Y., Donovan B., Bradshaw C.S., Fairley C.K. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011, 87(7):544-547.
15. Bauer H.M., Wright G., Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health 2012, 102(5):833-835.
16. Leval A., Herweijer E., Arnheim-Dahlstrom L., et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012, 206(6):860-866.
17. Baandrup L., Blomberg M., Dehlendorff C., Sand C., Andersen K.K., Kjaer S.K. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 2013, 40(2):130-135.
18. Nsouli-Maktabi H., Ludwig S.L., Yerubandi U.D., Gaydos J.C. Incidence of genital warts among U.S. service members before and after the introduction of the quadrivalent human papillomavirus vaccine. MSMR 2013, 20(2):17-20.
19. Palefsky J.M., Giuliano A.R., Goldstone S., et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011, 365(17):1576-1585.
20. Giuliano A.R., Palefsky J.M., Goldstone S., et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011, 364(5):401-411.
21. Stanley M. HPV vaccination in boys and men. Hum Vaccine Immunother 2014, 10(7):2109-2111.
22. de Sanjose S., Quint W.G., Alemany L., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11(11):1048-1056.
23. Serrano B., Alemany L., Tous S., et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agents Cancer 2012, 7(1):38.
24. Schiller J.T., Castellsague X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(Suppl. 5):F123-F138.
25. de Sanjose S., Alemany L., Ordi J., et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 2013, 49(16):3450-3461.
26. Alemany L., Saunier M., Alvarado-Cabrero I., et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer 2014, 136(1):98-107.
27. Alemany L., Saunier M., Tinoco L., et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur J Cancer 2014, 50(16):2846-2854.
28. Joura E., Giuliano A., Iversen O.E., et al. 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015, 372(8):711-723.
29. Van Damme P., Olsson S.-E., Block S. Immunogenicity and safety of a 9-valent HPV vaccine. Pediatrics 2015, 136(1):e28-e39.
30. Roberts C., Green T., Hess E., et al. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types. Hum Vaccine Immunother 2014, 10(8):2174-2183.
31. Brown M.J., Seitz H., Towne V., Muller M., Finnefrock A.C. Development of neutralizing monoclonal antibodies for oncogenic HPV types. Clin Vaccines Immunol 2014, 21(4):587-593.
32. Miettinen O., Nurminen M. Comparative analysis of two rates. Stat Med 1985, 4:213-226.
33. Hillman R.J., Giuliano A.R., Palefsky J.M., et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccines Immunol 2012, 19(2):261-267.
34. de Villiers E.-M., Fauquet C., Broker T.R., Bernard H.-U., zur Hausen H. Classification of papillomaviruses. Virology 2004, 324:17-27.
35. Fazekas S., Groth S., Webster R.G. Disquistions on original antigenic sin. J Exp Med 1966, 331-345.
36. Kim J.H., Skountzou I., Compans R., Jacob J. Original antigenic sin responses to influenza viruses. J Immunol 2009, 183(5):3294-3301.
37. Halstead S.B., Rojanasuphot S., Sangkawibha N. Original antigenic sin in dengue. Am J Trop Med Hyg 1983, 32(1):154-156.
38. Liu X.S., Xu Y., Hardy L., et al. IL-10 mediates suppression of the CD8 T cell IFN-gamma response to a novel viral epitope in a primed host. J Immunol 2003, 171(9):4765-4772.
39. Stanley M., Pinto L.A., Trimble C. Human papillomavirus vaccines-immune responses. Vaccine 2012, 30(Suppl. 5):F83-F87.
40. Brown D., Muller M., Sehr P., et al. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomavirus types 16 and 18. Vaccine 2014, 32(44):5880-5887.
41. Block S.L., Nolan T., Sattler C., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006, 118(5):2135-2145.
42. World Health Organization Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines. WHO Expert Committee on Biological Standardization. 57th Report 2006, World Health Organization, Geneva.
43. Iversen O.E. Long-term extension study of Gardasil in adolescents; results through month 96. EUROGIN 2013 2013, Available at 〈http://www eurogin com/2013/images/pdf/eurogin-2013-abstracts-part-2 pdf〉 (page 203). Accessed January 12, 2014].
44. Nygard M., Kjaer S., Dillner J., et al. Evaluation of the long-term anti-HPV 6, 11, 18 and 18 immune responses generated by GARDASIL. Clin Vaccines Immunol 2015, (epub ahead of print).
45. Palefsky J. Long-term effectiveness, tolerability and immunogenicity of quadrivalent HPV vaccine in men. EUROGIN 2013 2013, Available at 〈http://www eurogin com/2013/images/pdf/eurogin-2013-abstracts-part-2 pdf〉 (page 206) [accessed November 24th, 2014;-Long-term effectiveness, tolerability and immunogenicity of quadrivalent HPV vaccine in men. Accessed January 12, 2014].
46. Garland S.M., Cheung T.-K., McNeill S., et al. Safety and immunogenicity of a 9-valent HPV vaccine in females12-26 years of age who previously received the quadrivalent HPVvaccine. Vaccine 2015, 33(48):6855-6864.